Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

Also called NCT02545933

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 130 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02545933
Other papers using this trial's data
  • Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study Journal of the American Heart Association, 2020-04-21 DOI, PubMed 32306797, PMC7428520 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02545933. Randomized; no masking; primary purpose treatment. Start 2016-02 (actual); primary completion 2019-05 (actual). Results posted on 2020-08-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
Acronym
VORA-PRATIC
Intervention (Drug)
Prasugrel
Intervention (Drug)
Vorapaxar
Intervention (Drug)
Aspirin
Intervention (Drug)
Ticagrelor
Lead sponsor
University of Florida (class: other)
Collaborator
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct02545933
Content hash
7e5bcd59c83883da8c2467cc76202ae4d7ab81d7256116150b75e1a03de6e481